Fig. 6: Real-time and in vivo NIRF imaging of orthotopic HCC.
From: Nitrile-aminothiol bioorthogonal near-infrared fluorogenic probes for ultrasensitive in vivo imaging
a Chemical structure of CyNAP-SS-FK and the control probe CyNAP-T. b Schematic illustration of the development of orthotopic liver tumor model and NIRF imaging at different post tumor implantation time points. c Representative NIRF images of living mice after injection of CyNAP-SS-FK or CyNAP-T at different post tumor implantation timepoints. The white circles indicate the liver (Li) or bladder (Bl). NIRF images acquired at 710 nm upon excitation at 660 nm. d The dynamic NIRF intensities of liver in living mice as a function of time after injection of CyNAP-SS-FK or CyNAP-T for different groups (n = 3, mean ± s.d.). Two-tailed Student’s t test; Day-0 group versus different tumor incubation time groups. NS, no statistically significant differences. e, f Representative confocal fluorescence microscopy images of regional liver slices and photomicrographs of haematoxylin and eosin staining in paraffin-embedded liver sections from different mice groups. The blue, green and red signals originate from 4,6-diamidino-2-phenylindole (DAPI), Cat B antibody staining and CyNAP-SS-FK, respectively (scale bar, 200 µm). NIRF images acquired at excitation at 594 nm. Each experiment was repeated at least for 3 times. g The IVIS imaging images of the organs of mice after injection of CyNAP-SS-FK about 12 h. Data are the mean ± SD. n = 3 independent experiments. h Quantified mean fluorescence intensity (MFI) in Fig. 6c (n = 3, mean ± s.d.). Two-tailed Student’s t test; Day-0 group versus different tumor incubation time groups. *p < 0.05, **p < 0.01, ***p < 0.001, NS, no statistically significant differences. i-j Measurements of liver function in the mouse model of orthotopic liver cancer. Levels of ALT and AST at different groups (n = 5, mean ± s.d.). Two-tailed Student’s t test; Day-0 group versus different tumor incubation time groups. NS, no statistically significant differences. k Quantified SBRs of CyNAP-SS-FK or CyNAP-T at 12 h post-injection time for different groups. Levels of SBRs at different groups (n = 3, mean ± s.d.). l Schematic illustration of detection timeline of HCC comparing CyNAP-SS-FK to the clinical and preclinical assays. m Comparison of the retention effect and SBRs of CyNAP-SS-FK or CyNAP-T in entire tumor imaging window period. Source data are provided as a Source Data file.
